What glaxosmithkline canada e does

GlaxoSmithKline Canada (legal entity GlaxoSmithKline Inc.) is the Canadian operating subsidiary of GSK plc, a global biopharma company listed on the London Stock Exchange and New York Stock Exchange (ticker: GSK). The company is headquartered in Mississauga, Ontario, with regional offices in Montreal, Quebec, and a vaccine manufacturing facility in Ste-Foy, Quebec City. GSK Canada employs approximately 1,629 full-time employees across the country and has invested $2.8 billion in Canadian medicines and vaccines R&D since 2000. Its purpose is to discover, develop, and deliver prescription medicines and vaccines across four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

The company's core technology centers on biopharmaceutical R&D, with proprietary platforms including long-acting monoclonal antibodies (notably depemokimab/Exdensur, an anti-IL-5 biologic with extended half-life enabling twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps) and recombinant vaccine technology with the proprietary AS01B adjuvant system used in Shingrix. Key commercial products include Exdensur (depemokimab), Shingrix (Recombinant Zoster Vaccine, now in prefilled syringe presentation), BLENREP for multiple myeloma, and the Stiefel dermatology sub-brand. ViiV Healthcare, a specialty HIV company majority-owned by GSK with minority stakes held by Pfizer and Shionogi, is operated in Canada under GSK's commercial umbrella. Other partnerships include Stiefel for dermatology products.

The business model is a traditional specialty biopharma commercial operation: prescription medicines and vaccines are sold through retail pharmacies, hospital pharmacies, and direct distribution to healthcare providers and institutions, with field sales representatives targeting prescribers supported by medical science liaisons. Revenue is generated through one-time product sales (patented and proprietary pharmaceuticals and vaccines) under government-determined reimbursement and pricing frameworks negotiated with federal and provincial health authorities and private payers. Customers span three segments — patients, healthcare professionals (physicians, specialists, pharmacists), and government/healthcare systems — with marketing focused on HCP engagement portals (GSKpro, GSK Medical), press releases for product launches, and patient advocacy partnerships for disease awareness campaigns.

Name

glaxosmithkline canada e

Legal name

GlaxoSmithKline Inc.

Website

https://gsk.ca

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

GlaxoSmithKline Canada is the Canadian subsidiary of global biopharma GSK plc, employing ~1,629 staff across Mississauga, Montreal, and Ste-Foy. It discovers, develops, and delivers prescription medicines and vaccines across respiratory, immunology, oncology, HIV, and infectious diseases, selling through pharmacies and direct to healthcare providers.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals and Vaccines

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)

Keywords

• Specialty pharmaceuticals
• Biologics manufacturing
• Vaccines production
• Respiratory therapeutics
• HIV treatments

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Discovery, development and delivery of prescription medicines and vaccines for patients. Revenue generated from sale of patented and proprietary pharmaceutical products across therapeutic areas including respiratory, immunology, oncology, HIV, and infectious diseases.
2. Vaccines: Development and sale of vaccines including Shingrix for shingles prevention and other vaccine products manufactured at Canadian facilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

GSK Canada is a biopharma company that discovers, develops, and delivers specialty medicines, vaccines, and general medicines for human health across four therapeutic areas: respiratory/immunology and inflammation, oncology, HIV, and infectious diseases. The company also operates the Stiefel dermatology sub-brand and represents ViiV Healthcare HIV products in Canada, with manufacturing capability at the Ste-Foy vaccine production facility.

Product overview

GSK Canada is a biopharma company offering specialty medicines and vaccines. Key products include EXDENSUR (depemokimab), the first and only long-acting biologic with twice-yearly dosing for severe asthma and chronic rhinosinusitis with nasal polyps; BLENREP for specific therapeutic applications; Shingrix, a recombinant zoster vaccine now available in prefilled syringe; and the Stiefel dermatology brand. The company also provides Patient Support and Healthcare Support Services to help patients access medications. Product portfolio spans respiratory/immunology, oncology, HIV, and infectious diseases, with R&D focus on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

Differentiator

Problem solved

Functional benefit

Brands

• Stiefel: Dermatology products brand operated by GSK
• ViiV Healthcare
• GSKpro
• GSK Medical

Products and services

• Exdensur (depemokimab) Long-acting monoclonal antibody targeting interleukin-5 (IL-5) for twice-yearly dosing. Approved as add-on maintenance treatment for severe asthma with eosinophilic phenotype (adults and adolescents 12+) and chronic rhinosinusitis with nasal polyps (adults).
• BLENREP (belantamab mafodotin) A specialty medicine product available in Canada for multiple myeloma treatment, with product monograph and patient information resources available to healthcare professionals.
• Shingrix (Recombinant Zoster Vaccine) Recombinant Zoster Vaccine (RZV) combining glycoprotein E antigen with AS01B adjuvant system. Licensed for shingles prevention in adults 50+ and immunocompromised adults 18+. Now available in prefilled syringe presentation.
• Stiefel Dermatology Dermatology brand under GSK focusing on skin health products and treatments for various dermatological conditions.

Quantifiable outcome

• Depemokimab demonstrated significant reduction in asthma exacerbation rate versus placebo in SWIFT phase III trials
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• ViiV HealthcarecoreStrategic or Co-development PartnerViiV Healthcare is a specialty HIV company majority-owned by GSK, dedicated to advances in HIV treatment and prevention. GSK Canada represents ViiV Healthcare operations in Canada, with General Manager Luis Morales sitting on the Canadian Country Executive Board.
• Stiefel (Dermatology)coreStrategic or Co-development PartnerStiefel, a GSK company, focuses on dermatology products and treatments, operated as part of GSK's product portfolio in Canada.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Merck Canada: Merck Canada (operating as MSD in many markets) is the Canadian subsidiary of Merck & Co., a leading vaccines and oncology player. It is a direct peer given overlapping franchises (vaccines, oncology, specialty medicines), a comparable enterprise sales motion, and parallel regulatory and reimbursement dynamics in Canada.
• Novartis Pharmaceuticals Canada: Novartis Pharmaceuticals Canada is the Canadian subsidiary of Novartis AG, a global biopharma with diversified specialty and innovative medicine franchises. It is a direct peer through overlapping specialty pharma operations, similar enterprise sales and medical affairs models, and shared regulatory and reimbursement dynamics.
• Gilead Sciences Canada: Gilead Sciences Canada is the Canadian subsidiary of Gilead Sciences, Inc., a global biopharma with leadership in HIV, viral hepatitis, and oncology. It is a direct peer through direct competition with ViiV Healthcare Canada (GSK majority-owned) in HIV treatment and prevention and overlapping public health engagement.
• Pfizer Canada: Pfizer Canada is the Canadian subsidiary of Pfizer Inc., a major global biopharma. It is directly comparable to GSK Canada as a large, diversified pharmaceutical company in Canada operating across vaccines, specialty medicines, and primary care, with similar field sales, pharmacy distribution, and HCP engagement models.
• AstraZeneca Canada: AstraZeneca Canada is the Canadian subsidiary of AstraZeneca plc, a global biopharma with deep respiratory and oncology franchises. It is a direct peer through competing respiratory biologics (Fasenra, Tezspire) targeting the same severe asthma patient population as EXDENSUR, with similar field sales and reimbursement dynamics.
• Roche Canada: Roche Canada is the Canadian subsidiary of F. Hoffmann-La Roche AG, a global biopharma with a strong oncology and biologics portfolio. It is a direct peer given a comparable specialty/biologics business model, parallel HCP engagement, and shared exposure to Canadian payer and reimbursement systems.
• Johnson & Johnson Innovative Medicine Canada: Johnson & Johnson Innovative Medicine Canada is the Canadian specialty biopharma subsidiary of Johnson & Johnson. It is a direct peer across immunology, oncology, and pulmonary hypertension franchises with comparable field sales, medical affairs, and reimbursement strategies in Canada.
• Sanofi Canada: Sanofi Canada is the Canadian subsidiary of Sanofi, a global biopharma with a strong vaccines portfolio (Sanofi Pasteur) and a specialty care franchise. It is a direct peer through Dupixent (co-promoted with Regeneron) competing with EXDENSUR in asthma/CRSwNP and parallel vaccine manufacturing and distribution operations.
• Bristol Myers Squibb Canada: Bristol Myers Squibb Canada is the Canadian subsidiary of Bristol Myers Squibb Company, a global biopharma with a strong oncology and specialty medicines franchise. It is a direct peer given parallel oncology (BLENREP competes in multiple myeloma) and immunology operations and similar HCP-focused commercial and market access models.
• AbbVie Canada: AbbVie Canada is the Canadian subsidiary of AbbVie Inc., a global biopharma with leadership in immunology and oncology. It is a direct peer through competing immunology/respiratory biologics (e.g., Skyrizi, Rinvoq) and a parallel specialty biologic commercial model targeting prescribers and payers in Canada.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about glaxosmithkline canada e